Carcinoma, Hepatocellular
8 competing products in clinical development for Carcinoma, Hepatocellular.
Pipeline by Phase
Pre-clinical3
Phase 11
Phase 21
Phase 32
Approved1
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Lenvatinib + Pembrolizumab + Oral Placebo + IV Placebo | Eisai | Phase 3 | Active | 44 |
| Lenvatinib | Eisai | Approved | Completed | 43 |
| lenvatinib + pembrolizumab + saline placebo | Eisai | Phase 3 | Completed | 40 |
| Lenvatinib + Nivolumab | Eisai | Phase 1 | Completed | 29 |
| Lenvatinib | Eisai | Phase 2 | Terminated | 27 |
| Lenvatinib | Eisai | Pre-clinical | Completed | 26 |
| Lenvatinib + Sorafenib | Eisai | Pre-clinical | Completed | 26 |
| Lenvatinib | Eisai | Pre-clinical | Completed | 26 |